Presentation is loading. Please wait.

Presentation is loading. Please wait.

Andre Goy, MD Cancer Center Director Lymphoma Division Head John Theurer Cancer HUMC, NJ Chief Science Officer Research / Innovation RCCA Professor.

Similar presentations


Presentation on theme: "Andre Goy, MD Cancer Center Director Lymphoma Division Head John Theurer Cancer HUMC, NJ Chief Science Officer Research / Innovation RCCA Professor."— Presentation transcript:

1 Andre Goy, MD Cancer Center Director Lymphoma Division Head John Theurer Cancer HUMC, NJ Chief Science Officer Research / Innovation RCCA Professor of Medicine at Georgetown MCL: Should all Eligible patients with MCL receive HDT-ASCT upfront?

2 MCL – Clinical Course – EU MCL Network CR-CRu 20-25%

3 MCL: High-Dose Therapy as Consolidation CHOP-> ASCT >CHOP-IFN 69 / 75 pts Dreyling M, et al. Blood. April 2005 ResponseIFN arm ASCT armp value Med DOR3.7y1.6 y ITT med TTF1.4y2.6y OS5.4 y

4 MCL – Management – 4 Phases Induction Consolidation Maintenance Salvage BEFORE CVP, CHOP, FC, CBL Nothing or HDT-ASCT Nothing or IFN More chemo…? Very short response to salvage chemo even with HDT-ASCT More chemo…? Very short response to salvage chemo even with HDT-ASCT Frequent chemoresistance

5 MCL – Management – 1 st Challenge Decide when to treat and recognize “indolent” MCL MIPI Ki-67 Hoster, Blood Jan 2008 Determann, Blood Dec 2007 Indolent?

6 MCL – Management – 1 st Challenge Decide when to treat and recognize “indolent” MCL Fernandez, Can Res, Feb 2010

7 MCL – Management – 1 st Challenge Recognize “indolent” MCL iMCL vs. cMCL Fernandez, Can Res, Feb 2010

8 MCL – Important Steps – Induction Therapy Geisler, Leuk Lymphoma, Aug 2009

9 MCL – Important Steps – Rituximab Impact Meta analysis showed > OS with R-chemo Schulz, J Natl Cancer Inst, May 2007 Griffith et al, Blood 2011; SEER data Elderly “real world” / TTNT med 11 ms, med OS 27 vs 37 ms

10 MCL – Important Steps- Rituximab / R-chemo ResponseCHOPR-CHOPp ORR74%94%0.005 CR7%34% TTF14 ms21 ms0.01 Lenz, JCO, March 2005; Hoster ASH 2008 Schulz, J Natl Cancer Inst, May 2007; Griffith et al, Blood 2011; SEER data PFSTTNT OS Rituximab increases ORR, CR rate but med 25%!!! 59 / 62 pts

11 MCL: ASCT remains Relevant in R-chemo Era ASCT vs. Maint IFN in R-chemo era Hoster, ASH 2008 ASCT remains relevant in the R-chemo era Pooled younger / older HDT /vs. stand + maint IFN

12 DIT/ASCT Have Also an Impact Outside of Clinical Trials 167 MCL pts NCCN database – frontline R-chemo - NOT on trial LaCasce A, et al. Blood, 2012 Mar 1;119(9): OS K-Mp R-HyperCVAD vs R-CHOPP <.04 R-CHOP/ASCT vs R-CHOPP <.20 R-HyperCVAD vs R-CHOP/ASCTTP =.64 PFS OS 3y PFS R-CHOP 18% 3 times < to any dose- intensive strategy (56-58%) When pooling DI-HDT pts / R-CHOP >>> PFS and OS (p=0.001)

13 MCL - Important Steps - Induction Impact Prior to ASCT (R)-CHOP-DHAP  ASCT Tripled CR rate after R-DHAP (12% vs. 61%) Med EFS: 84 ms vs. 51 ms prior to rituximab EFS Delarue, Blood Jan 2013 OS

14 MCL – Important Steps- Induction Impact Prior to ASCT Geisler, Blood, July y / same benefit MCL 2: 55% CR-CRu post induction

15 MCL – Important Steps- Induction Impact Prior to ASCT Geisler, Blood Feb 2010 Geisler, Br JnlHeamatol, Aug 2012 Median follow-up of 6·5 years More than 70% of patients with low- intermediate MIPI-B were alive at 10 years Geisler, Br JnlHeamatol, Aug 2012

16 MCL - Important Steps - Induction Impact Prior to ASCT Geisler, Blood Feb Multicenter setting - Med age 56 y (32-65) -Median OS and median response duration BOTH not reached at 10 years

17 MCL - Important Steps - R/AraC Induction Impact 1. Cortelazzo S, et al. ASH Abstract Romaguera JE, et al. J ClinOncol. 2005;23: Fayad L, et al. Clin Lymphoma Myeloma. 2007;8, Delarue, Blood Jan 2013 R-CHOP 2y PFS 25% !! StudyTherapy5-Yr EFS, % GITIL [2] (R) HDS-ASCT*61% MDACC [3,4] R-HyperCVAD60% / FFS CALGBR-Maxi CHOP-MTX / VP16-AraC/ CBV- ASCT 56% / PFS EU (GELA)R-CHOP/DHAP- TAM  ASCT 65% / TTF

18 MCL - Important Steps - R/AraC Induction Impact MCL Younger < 65 years R Dexa BEAM Cyclo TBI + Autograft P B S C harvest Ara-C, Melphalan TBI + Autograft 3-monthly follow-up week R-CHOP/R-DHAP alternating 3-weekly week R-CHOP 3-weekly 3-monthly follow-up P B S C harvest MRD MRD 2-3 monthly intervals Hermine et al, ASH 2010 abst # 110 AraC benefit confirmed in randomized trial

19 MCL - Important Steps - R/AraC Induction Impact Hermine et al, ASH 2010 abst # 110 / ASH 2012 abst # 151 months TTFT (Primary endpoint) Remission Duration after ASCT w/ med follow up 51 ms, TTF 46 vs 88 ms, p0.038 w/ med follow up 51 ms, remission duration 49 vs 84 ms, p pts R-CHOP/ 208 pts R-CHOP/DHAP No diff between arms in pts characteristics or % pts going ASCT (77% / 79%)

20 MCL - Important Steps - R/AraC Induction Impact Hermine et al, ASH 2010 abst # 110 / ASH 2012 abst # 151 HD AraC translates into > OS as well

21 MCL – Important Steps Benefit in all MIPI groups: TTF ITT Hermine O, et al. ASH Abst # 151 Ki67 in low MIPI

22 MCL – Important Steps Hermine O, et al. ASH Abst # 151

23 MCL – Important Steps Hermine O, et al. ASH Abst # 151 Remission duration based on clinical and mol response after induction

24 EU - MCL Younger Pts - Results Hermine et al, ASH 2010 abst # 110 / ASH 2012 abst # 151 R-CHOPR-DHAP PBBMPBBM % MRD negative 54% 70% p = 0.04p = % 60% 82% 73% 87% ns * * ** Impact of ASCT on MRD status

25 MCL – Younger Pts – Frontline Summary –Arm R-CHOP-DHAP leads to > outcome TTF, DOR and now OS –Due to higher and earlier rate of CR-CRu and molecular CR in HD AraC arm POST induction ++ Med OS AraC arm NR vs 82 ms, p ParameterR-CHOP/R-DHAPR-CHOPp CR-CRu55%40%p= Mol CR83%51%p < Hermine et al, ASH 2010 abst # 110 / ASH 2012 abst # 151 Post ASCT similar CR-CRu (79/82%)

26 MCL – Important Steps – ASCT remains relevant in the R-chemo Era TTF w/ R-CHOP vs. R-CHOP/R-DHAP  ASCT Hoster, AH 2008

27 MCL – Important Steps – DIT/ASCT remains relevant in the R-chemo Era “Longest mileage” Cost

28 MCL - DIT/HDT-ASCT - Summary –Med OS improvement recognized mostly due to long unprecedented PFS > 5y with DIT and /or HDT-ASCT (40% MCL are <60y) –Achieving a deep and early response in MCL matters –A CR  translates into >> outcome –Molecular CR ++ might become new surrogate endpoint

29 MCL – DIT-ACST Remains the Best Option in R-Chemo Era –Clearly subset of MCL that are more indolent (nonnodal leukemic phase, hypermutated & SOX11 -ve) –Novel therapies very promising  Platform for combinations (improve mol CR) and /or maintenance post therapy  Alternative to chemotherapy (in elderly)

30 MCL – Management – DIT/ASCT Fit Pts Induction NOW and FORWARD Mol CR as a new endpoint? Beyond standard chemo in MCL Induction: R-chemo with cytarabine Consolidation Still longest PFS Will MOL CR early still need ASCT? Maintenance Still late relapses Novel therapies? PCR based? Novel therapies? PCR based? Salvage Role of HDT/ASCT debated Novel therapies combos? Mini allo? CAR? Novel therapies combos? Mini allo? CAR?

31 Thank you!


Download ppt "Andre Goy, MD Cancer Center Director Lymphoma Division Head John Theurer Cancer HUMC, NJ Chief Science Officer Research / Innovation RCCA Professor."

Similar presentations


Ads by Google